Sidra Medicine, a member of Qatar Foundation, is taking a groundbreaking step towards transforming precision healthcare through clinical trials, offering hope to young patients with rare and complex diseases. The Clinical Trials Program at Sidra Medicine aims to focus on clinical trials that will benefit children in the Arab region, especially those with rare diseases that lack effective treatment options. This initiative will position Sidra Medicine as a regional leader in clinical research, offering personalized treatment options to children with rare diseases.
Dr. Iyabo Tinubu-Karch, Chief Executive Officer at Sidra Medicine, emphasized the importance of advancing pediatric healthcare and pioneering new medications and therapies. Clinical trials are the final step of medical research, where new treatments undergo evaluation for safety and effectiveness before being widely available. By participating in clinical trials, children have the opportunity to receive potentially life-changing treatments before they are accessible to the general public.
Prof. Khalid A. Fakhro, Chief Research Officer at Sidra Medicine, highlighted the institution’s dedication towards complex research, including Phase 1 through Phase 4 studies, establishing them as a regional leader in clinical trials. The lack of research within the Arab population has resulted in a data gap, hindering the development of effective and personalized treatments. The clinical trials at Sidra Medicine will address this gap, building a robust database of knowledge to tailor treatments to the unique needs of the population.
Dr. Chiara Cugno, Director of Advanced Cell Therapy Core at Sidra Medicine, emphasized the significance of representing Middle Eastern pediatric populations in clinical trials from the beginning of the drug testing process. The program aims to offer personalized experimental solutions and hope to families with genetic ancestries that have been overlooked in current treatment options. Initial focus will be on disorders and medical conditions like endocrine disorders, neuromuscular conditions, metabolic disorders, and pediatric cancers.
Sidra Medicine’s participation in global healthcare institutions and selection as a site for pharma-sponsored industry clinical trials showcases the credibility of their research, expertise, and technologies. Every clinical trial at Sidra Medicine will undergo intense examination to ensure the well-being of every patient, with adherence to the highest international ethical and scientific standards. Families play a crucial role in supporting personalized medicine by voluntarily enrolling their children in research studies and clinical trials.
Dr. Ahmed Al Hammadi, Acting Chief Medical Officer at Sidra Medicine, highlighted the importance of families becoming partners in developing future treatments by enrolling their children in clinical trials. The potential impact of one child’s clinical trial extends to improving the care, treatment, and well-being of many other children. Sidra Medicine’s commitment to personalized medicine aims to provide opportunities for families in Qatar to participate in clinical trials, eliminating the need to relocate abroad.
